Mersana Therapeutics, Inc. - Special Call Transcript
Good morning, and welcome to the Mersana Therapeutics Conference Call to Review Interim XMT-1536 Phase I Dose Expansion Data in Ovarian Cancer. (Operator Instructions)
I would now like to turn the call over to Sarah Carmody, Executive Director, Investor Relations and Corporate Communications. Please proceed.
Good morning, and welcome to our call. Earlier this morning, we issued a press release providing updated interim data on the ovarian cancer cohort of the expansion portion of our Phase I study of XMT-1536. This release as well as the slides we will present today are available on the Investors & Media section of our website at www.mersana.com. A replay of today's call will also be made available. After our prepared remarks, we will open the call for Q&A.
Before we begin, I'd like to mention that our call will contain forward-looking statements within the meaning of
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |